NGEN.V · NervGen Pharma Corp

-

Please sign in to comment on NGEN.V

1 Comment

Admin

4 years ago

NervGen Pharma Corp is currently in a long term downtrend where the price is trading 6.9% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

NervGen Pharma Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 8.5% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 47.0% to $-1M since the same quarter in the previous year.

Based on the above factors, NervGen Pharma Corp gets an overall score of 3/5.

Exchange	V
CurrencyCode	CAD
ISIN	CA64082X2032
Sector	Healthcare
Industry	Biotechnology

Market Cap	209M
PE Ratio	None
Target Price	4.975
Beta	0.7
Dividend Yield	None

ABOUT

NervGen Pharma Corp

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

NGEN.V · NervGen Pharma Corp

-

NervGen Pharma Corp

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest NervGen Pharma Corp using a moving average strategy